What is the role of octreotide in the treatment of high-grade malignant neuroendocrine tumors (G3NETs) and neuroendocrine carcinomas (NECs)?

Label:chem

Topic
Octreotide is a somatostatin analog (SSA) that has been used in the treatment of neuroendocrine tumors (NETs) due to its ability to bind to somatostatin receptors (SSTRs), particularly SSTR2, and inhibit cell proliferation. It has shown efficacy in low-grade and moderate-grade NETs, but its effectiveness in high-grade NETs and NECs has not been well-established.
Answer
The study found that traditional SSA octreotide was ineffective in patients with NET G3 and NEC, despite the expression of somatostatin receptors in these tumors. This suggests that octreotide may not be a suitable treatment option for these aggressive tumors.
Return to Home Chemical List
Knowledge you may be interested in
What are the potential mechanisms underlying the differential effects of atomoxetine in LB and SB mice? How does atomoxetine influence anxiety and aversive behavior in mice with different brain weights? How does atomoxetine affect cognitive test performance in mice with different brain weights? How does the price of atomoxetine on the black market compare to its prescribed form? What are the potential reasons for the black market demand for atomoxetine? What is the significance of analyzing black market sales of atomoxetine? What are the findings regarding the structural and chemical integrity of atomoxetine in SLS 3D printed tablets? What is the significance of using hydroxypropyl methylcellulose (HPMC) in the formulation of SLS 3D printed atomoxetine tablets? How to evaluate the physical and mechanical properties of atomoxetine tablets produced using SLS 3D printing? What is the effect of β-Galactosylceramide (GalCer) on stratum corneum intercellular lipid synthesis and skin barrier function in a three-dimensional cultured human epidermis model? What is the role of pasireotide in the treatment of high-grade malignant neuroendocrine tumors (G3NETs) and neuroendocrine carcinomas (NECs)? How does the expression of somatostatin receptors (SSTRs) correlate with the effectiveness of octreotide and pasireotide in treating high-grade neuroendocrine tumors? How does the pharmaceutical peptide octreotide respond to changes in relative humidity and temperature? What is the role of octreotide-functionalized ⁶⁸Ga-radiolabeled nanodiamonds in tumor targeting? What is the mechanism of action of NUC-1031 when combined with cisplatin in treating biliary tract and ovarian cancer? How does NUC-1031 overcome the limitations of gemcitabine in cancer treatment? What is the role of RRM1 in the mechanism of action of NUC-1031 and its clinical implications? How does the combination of NUC-1031 and cisplatin affect cell cycle progression and DNA damage in cancer cells? What is NUC-1031 and its role in the treatment of advanced biliary tract cancer (aBTC)? Why did the phase III NuTide:121 trial fail to show improved overall survival with NUC-1031?